Regentis Biomaterials Ltd. (RGNT) Key Metrics
RGNT valuation today
Trailing 12 months · as of October 18, 2026- Market cap
- $10.5M
- Enterprise value
- $5.8M
- P/E (TTM)
- —
- Forward P/E
- —
- PEG ratio
- —
- Price / sales
- —
- Price / book
- 1.9
- EV / EBITDA
- —
- Dividend yield
- —
- Beta
- —
RGNT key metrics, 2022–2025
Fiscal year ended December 31, 2025 · U.S. dollarsRGNT returns How much profit the business earns on the capital it uses.
RGNT per-share figures Results divided by the shares outstanding at year-end.
RGNT financial health Debt, liquidity and how easily interest is covered.
RGNT valuation history
RGNT returns on capital
Net income (ROE, ROA) or after-tax operating income (ROIC) divided by the average of the opening and closing balance.
RGNT debt vs cash
Debt includes short- and long-term borrowings and, where reported, lease liabilities.
RGNT price vs earnings per share
RGNT key metrics
2022–2025| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Valuation | ||||
| Market capitalization | $34.9M | — | — | — |
| Enterprise value | $27.5M | — | — | — |
| Price / book | 7.4 | — | — | — |
| Earnings yield | −39.1% | — | — | — |
| Free cash flow yield | −3.9% | — | — | — |
| Share price at fiscal year-end | $6.74 | — | — | — |
| Per share | ||||
| Revenue per share | $0.00 | $0.00 | $0.00 | $0.00 |
| Earnings per share | −$2.64 | $0.93 | −$0.84 | −$0.29 |
| Operating cash flow per share | −$0.27 | −$0.12 | −$0.25 | −$0.31 |
| Free cash flow per share | −$0.27 | −$0.12 | −$0.25 | −$0.31 |
| Cash per share | $1.42 | $0.04 | $0.07 | $0.25 |
| Book value per share | $0.92 | −$7.94 | −$9.31 | −$8.53 |
| Tangible book value per share | $0.92 | −$7.94 | −$9.31 | −$8.53 |
| Capex per share | $0.00 | $0.00 | $0.00 | $0.00 |
| Debt per share | — | — | $1.50 | $1.31 |
| Shares outstanding | 5.2M | 5.2M | 4.9M | 4.9M |
| Change in shares outstanding | 0.0% | +5.1% | 0.0% | — |
| Returns & profitability | ||||
| Return on assets (ROA) | −337.0% | — | −397.9% | −84.4% |
| Return on tangible assets | −179.2% | 996.1% | — | −84.4% |
| Income quality (OCF / net income) | — | −0.13 | — | — |
| Financial health | ||||
| Total debt | — | — | $7.4M | $6.5M |
| Cash & short-term investments | $7.4M | $229,000 | $345,000 | $1.2M |
| Net debt | −$7.4M | −$229,000 | $7.1M | $5.2M |
| Debt / assets | — | — | 20.57 | 3.77 |
| Net debt / EBITDA | — | −0.05 | — | — |
| Current ratio | 2.65 | 0.07 | 0.11 | 0.66 |
| Quick ratio | 2.65 | 0.07 | 0.11 | 0.66 |
| Interest coverage | -26.6 | 5.5 | -11.2 | — |
| Working capital | $4.7M | −$6.0M | −$2.8M | −$892,000 |
| Invested capital | −$2.6M | −$41.3M | −$38.8M | −$36.8M |
| Tangible asset value | $4.7M | −$41.1M | −$45.9M | −$42.1M |
| Net current asset value | $4.7M | −$41.1M | −$45.9M | −$42.1M |
| Graham net-net per share | $0.87 | −$7.98 | −$9.32 | −$8.63 |
| Efficiency | ||||
| Asset turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Average payables | $259,000 | $302,500 | $279,500 | $206,000 |
| Intangibles / total assets | 0.0% | 0.0% | 0.0% | 0.0% |
Computed from RGNT's annual financial statements (latest annual report filed —) and the closing share price on each fiscal year-end, adjusted for stock splits. Figures in U.S. dollars; data from EODHD. Averages use the opening and closing balance of each year.
RGNT valuation and financial ratios
See the RGNT income statement, the RGNT chart for price history, or the RGNT stock overview for the latest quote and news.
RGNT key metrics FAQ
What is Regentis Biomaterials's free cash flow yield?
Regentis Biomaterials generated -$1.4 million of free cash flow in fiscal 2025, a free cash flow yield of −3.9% on its market value at year-end ($34.9 million).
What is Regentis Biomaterials's current ratio?
Regentis Biomaterials's current ratio was 2.65 at the end of fiscal 2025: current assets were 2.65 times current liabilities.